Prodrugs of 9-benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: Potent interferon inducing agents in monkeys

Chemical and Pharmaceutical Bulletin

Volumn 52, Issue 4, 2004, Pages 466-469

  Kurimoto, Ayumu ^a   Tobe, Masanori ^a   Ogita, Haruhisa ^a   Ogino, Tetsuhiro ^a   Takaku, Haruo ^a   Ichii, Shinji ^a   Kawakami, Hajime ^a   Isobe, Yoshiaki ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

8 hydroxyadenine; Antiviral; Interferon inducing agent; Prodrug

Indexed keywords

9 BENZYL 2 (2 HYDROXYETHYLTHIO) 8 ISOBUTOXYCARBONYLOXYADENINE; 9 BENZYL 2 (2 HYDROXYETHYLTHIO) 8 ISOPROPOXYCARBONYLOXYADENINE; 9 BENZYL 2 (2 HYDROXYETHYLTHIO) 8 METHOXYCARBONYLOXYADENINE; 9 BENZYL 8 BUTOXYCARBONYLOXY 2 (2 HYDROXYETHYLTHIO)ADENINE; 9 BENZYL 8 BUTOXYCARBONYLOXY 2 [2 (BUTOXYCARBONYLOXY)ETHYLTHIO]ADENINE; 9 BENZYL 8 ETHOXYCARBONYLOXY 2 (2 HYDROXYETHYLTHIO)ADENINE; 9 BENZYL 8 ETHOXYCARBONYLOXY 2 [2 (ETHOXYCARBONYLOXY)ETHYLTHIO]ADENINE; 9 BENZYL 8 HYDROXY 2 (2 HYDROXYETHYLTHIO)ADENINE; 9 BENZYL 8 HYDROXY 2 [2 (BUTOXYCARBONYLOXY)ETHYLTHIO]ADENINE; INTERFERON INDUCING AGENT; PRODRUG; SM 295072; UNCLASSIFIED DRUG; 9-BENZYL-8-HYDROXY-2-(2-HYDROXYETHYLTHIO)ADENINE; ADENINE; DRUG DERIVATIVE; INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MONKEY; NONHUMAN; PROTEIN INDUCTION; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; AREA UNDER THE CURVE; CELL STRAIN CACO 2; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; MACACA; METABOLISM; SPRAGUE DAWLEY RAT; SYNTHESIS;

ADENINE; ANIMALS; AREA UNDER CURVE; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; HYDROXYLATION; INTERFERON INDUCERS; INTERFERONS; MACACA FASCICULARIS; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 7444264580     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.52.466     Document Type: Article

References (11)

1. St. Georgiev V., Trend Pharmacol. Sci., 8, 446-451 (1988).
2. Sen G. C., Lengyel P., J. Biol. Chem., 267, 5017-5020 (1992).
3. Dianzani F., J. Interferon Res., 12, 109-118 (1992).
4. Spiegel R. J., Urology, 34, 75-79 (1989).
5. Pfeffer L. M., Dinarello C. A., Herbermann R. B., Williams B. R. G., Borden E. C., Bordens R., Walter M. R., Nagabhushan T. L., Trotta P. P., Pestka S., Cancer Res., 58, 2489-2499 (1998).
6. Ashmed A., Keefe E. B., J. Gastroenterol. Hepatol., 14, S12-S18 (1999).
7. Rönnblom L. E., Janson E. T., Perers A., Öberg K. E., Alm G. V., Clin. Exp. Immunol., 89, 330-335 (1992).
8. Steis R. G., Smith J. W., Urba W. J., Clark J. W., Itri L. M., Evans L. M., Schoenberger C., Longo D. L., N. Engl. J. Med., 318, 1409-1423 (1988).
9. Hirota K., Kazaoka K., Niimoto I., Kumihara H., Sajiki H., Isobe Y., Takaku H., Tobe M., Ogita H., Ogino T., Ichii S., Kurimoto A., Kawakami H., J. Med. Chem., 45, 5419-5422 (2002).
10. Based on MEDI41 presented at the 224th ACS National Meeting, Boston, MA, U.S.A., on 18 August 2002.
11. Wagner T. L., Horton V. L., Carlson G. L., Myhre P. E., Gibson S. J., Imbertson L. M., Tomai M. A., Cytokine, 9, 837-845 (1997).